Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Université de Sherbrooke
With
AstraZeneca
Age
18–80
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
To have at least one of the following three risk factors:
* Tumour classified T3 or T4
* Gleason score 8-10
* Prostate-specific antigen (PSA) level \> 20
Performance status score of 0-1.
Patients must sign a consent form before the start of the study.
No evidence of regional disease: clinically negative regional adenopathies are revealed by imaging (computed axial tomography \[CAT\] scan, magnetic resonance imaging \[MRI\], lymphography) or surgical staging or negative pelvic node dissection.
No distant metastasis. These patients must all have a negative bone scan 12 weeks prior to randomization.
Hormonal therapy is allowed up to a maximum of two months before the consent form is signed, as long as the initial work-up was done, including having the requested deadlines respected.
Patients with a previous history of cancer are eligible on the condition that they have not had any disease progression for more than five years.
The patient must be available for treatments and follow-up visits.
Treatments must start in the three weeks following randomization.
You may not be if
Severe medical or psychiatric problems that could compromise study compliance.
Chronic hepatic disease, abnormal hepatic functions, i.e. aspartate aminotransferase, alanine aminotransferase \> 1.5 times the upper normal limit.
Clareo Health | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers
